Skip to main content

Table 2 Clinical practices compared between PDAC, PanNEC and PanNET

From: Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma

  PDAC PanNEC PanNET
Diagnosis
 Serum test CA199, CEA,CA125 NSE
CA199, CEA, AFP
CgA, 5-HIAA
Functional hormone
 Imaging Computer tomography
Magnetic resonance imaging
F18-FDG PET/CT
Computer tomography
Magnetic resonance imaging
F18-FDG PET/CT
Computer tomography
Magnetic resonance imaging
Ga68-DOTATATE PET/CT
Somatostatin receptor scintigraphy
Therapy
 Localized Resection
Neoadjuvent chemo + resection
Resection Active surveillance
Resection
 Advanced and metastasis SYSTEM TREATMENT
Irinotecan + Oxaliplatin + fluorouracil
Gemcitabine + Albumin-Paclitaxel
Clinical trials
OTHERS
Radiotherapy
SYSTEM TREATMENT
Etoposide + cisplatin
Irinotecan + cisplatin
Clinical trials
OTHERS
Radiotherapy
LOCAL TREATMENT
Debulking surgery
Transarterial chemoembolization, Ablation of liver metastasis
SYSTEM TREATMENT
Somatostatin analogs
Sunitinib and everolimus
Temozolomidecapecitabine
Follow-up 3 months 3 months Localized 6-12 months; Metastasis 3-6 months